Online inquiry

IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9636MR)

This product GTTS-WQ9636MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 608
UniProt ID P07766; Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9636MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13465MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ2916MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ7145MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ6977MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ3985MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BG9924
GTTS-WQ13339MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ8555MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ13518MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW